Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients

Transplantation

Volumn 61, Issue 4, 1996, Pages 546-554

  Nashan, B ^a   Schlitt, H J ^a   Schwinzer, R ^a   Ringe, B ^a   Kuse, E ^a   Tusch, G ^a   Wonigeit, K ^a   Pichlmayr, R ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INOLIMOMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SCREENING; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; AZATHIOPRINE; BACTERIAL INFECTIONS; CANDIDIASIS; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MICE; MIDDLE AGED; PROSPECTIVE STUDIES; RABBITS; RECEPTORS, INTERLEUKIN-2;

EID: 0029935097     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199602270-00006     Document Type: Article

References (37)

1. Starzl TE, Marchioro TL, Faris TD, Mc Cardle RJ, Iwasaki Y. Avenues of future research in homotransplantation of the liver with particular reference to hepatic supportive procedures, antilymphocytic serum and tissue typing. Am J Surg 1966; 112: 391.
2. Cosimi AB. The clinical value of antilymphocyte antibodies. Transplant Proc 1981; 13: 462.
3. Hotta SS. Assessment of liver transplantation. Health Techno Assess Rep 1990; 1: 1.
4. Cosimi AB, Colvin RB, Burton RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305: 308.
5. Thistlethwaite JR, Cosimi AB, Delmonico FL, et al. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation 1984; 38: 695.
6. Ortho Multicenter Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
7. Chatenoud L, Baudrihaye MF, Schindler J, Kreis H, Goldstein G, Bach JF. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982; 12: 979.
8. Oh CS, Stratta RJ, Fox BC, et al. Increased infections associated with the use of OKT3 for treatment of steroid resistant rejection in renal transplantation. Transplantation 1988; 45: 68.
9. Brouwer RML, Balk AHMM, Weimar W. Post-transplantation lymphoproliferative disorder and OKT3. N Engl J Med 1991; 324: 1437.
10. Cosimi AB, Jenkins R, Rohrer R, et al. A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients. Arch Surg 1990; 125: 781.
11. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB. Administration of an anti-interleukin-2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 1985; 162: 358.
12. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB. Therapy with a monoclonal antibody to the interleukin-2 receptor spares T suppressor cells and prevents/reverses acute allograft rejection. Proc Natl Acad Sci USA 1986; 83: 2624.
13. Reed MH, Shapiro ME, Strom TB. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation 1989; 47: 55.
14. Dendorfer U, Maslinski W, Remillard B, Strom TB. Interleukin-2 and the interleukin-2 receptor. Transplantation Science 1993; 3: 83.
15. Kondo M, Takeshita T, Ishii N, et al. Sharing of the interleukin-2 (IL-2) receptor g chain between receptors for IL-2 and IL-4. Science 1993; 262: 1874.
16. Russell SM, Keegan AD, Harada N, et al. Interleukin-2 receptor g chain: a functional component of the interleukin-4 receptor. Science 1993; 262: 1880.
17. Akbar AN, Salmon M, Janossy G. The synergy between naive and memory T cells during activation. Immunol Today 1991; 12: 184.
18. + T-cells. Cell Immunol 1992; 140: 31.
19. Kirkman RL, Shapiro ME, Carpenter DB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107.
20. Soulillou JP, Cantarovich D, LeMauff B, et al. Randomized controlled trial of monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
21. Hervé P, Wijdenes J, Bergerat JP, et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990; 75: 1017.
22. Wijdenes J, Clément C, Morel-Fourrier B, Béliard R, Hervé P, Peters A. A monoclonal antibody against the human IL-2 receptor with high inhibitory activity on IL-2 induced proliferation of T cells, experimental and clinical results. In: Kaplan JG, Green DR, Bleackly RC (eds). Cellular basis of immune modulation: progress in leukocyte biology. New York, Liss, 1989; 551.
23. Bethke U, Rohm D, Kloft M, Rudnick D, Kothe N. Development and application of media in the production of monoclonal antibodies. Dev Biol Stand 1990; 71: 55.
24. Wonigeit K, Kohlhaw K, Winkler M, Schäfer O, Pichlmayr R. Cyclosporin monitoring in liver allograft recipients: two distinct patterns of blood level derangement associated with nephrotoxicity. Transplant Proc 1990; 22: 1305.
25. Stratta RJ, Mason B, Lorentzen DF, et al. Cadaveric renal transplantation with quadruple immunosuppression in patients with a positive antiglobulin crossmatch. Transplantation 1989; 47: 282.
26. Nashan B, Schlitt HJ, Wittekind C, Ringe B, Wonigeit K, Pichlmayr R. Patterns of immune activation during the first four weeks in liver transplant patients. Transplant Proc 1989; 21: 3621.
27. Schlitt HJ, Nashan B, Ringe B, et al. Differentiation of liver graft dysfunction by transplant aspiration cytology. Transplantation 1991; 51: 786.
28. Dixon WJ, Brown MB, Engelmann L, Jennrich RJ. BMDP Statistical software manual, vol 2. Berkeley: University of California Press, 1990.
29. SAS/STAT guide for personal computers, version 6.04. Cary, NC: SAS Institute 1991.
30. Neuhaus P, Bechstein WO, Blumhardt G, et al. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 1993; 55: 1320.
31. Nashan B, Schwinzer R, Schlitt HJ, Wonigeit K, Pichlmayr R. Immunologic effects of the anti-IL-2 receptor monoclonal antibody BT 563 in liver allografted patients. Transplant Immunology 1995; 3: 203.
32. Reding R, Vraux H, de Ville de Goyet J, et al. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation. Transplantation 1993; 55: 534.
33. Abramovicz D, Schandenne L, Goldman M, et al. Release of tumor necrosis factor, interleukin 2, and gamma interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
34. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989; 320: 1420.
35. Schlitt HJ, Nashan B, Krick P, et al. Intragraft immune events after human liver transplantation. Transplantation 1992; 54: 273.
36. Dousset B, Hubscher SG, Padbury RTA, et al. Acute liver allograft rejection - is treatment always necessary? Transplantation 1993; 55: 529.
37. Otto G, Thies J, Kabelitz D, et al. Anti-CD25 monoclonal antibody prevents early rejection in liver transplantation - a pilot study. Transplant Proc 1991; 23: 1387.